18 F-FDG PET/CT in Local Ablative Therapies: A Systematic Review.
| Autor: | Aarntzen EHJG; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; and., Heijmen L; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; and., Oyen WJG; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; and wim.oyen@icr.ac.uk.; Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Department of Nuclear Medicine, London, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2018 Apr; Vol. 59 (4), pp. 551-556. Date of Electronic Publication: 2018 Jan 18. |
| DOI: | 10.2967/jnumed.117.198184 |
| Abstrakt: | Driven by the continuous improvement in the accuracy of cross-sectional imaging, image-guided minimally invasive local ablative therapies have received incremental interest over the past few years. In this article, we systematically review the currently available literature on 18 F-FDG PET/CT to monitor the efficacy of these local ablative therapies. By including all local ablative treatment modalities, tumor types, and organ sites, we provide a comprehensive overview of the current status, identify general patterns across studies, and provide recommendations for future studies and clinical practice. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria were used to assess the quality of the reported diagnostic accuracy of the retrieved studies. Data in the literature suggest that 18 F-FDG PET/CT is a highly accurate tool to assess the technical success of local treatment, to identify residual or recurrent tumor early after intervention, and to provide prognostic and predictive information. However, prospective interventional studies based on 18 F-FDG PET/CT findings of disease activity are mandatory to develop uniform and quantitative criteria for PET evaluation. Moreover, the optimal timing of 18 F-FDG PET/CT after treatment may vary according to the location of the disease, with very early imaging being possible in solid organs such as the liver but posttreatment imaging being challenging for 3 mo in a location such as the lung parenchyma. (© 2018 by the Society of Nuclear Medicine and Molecular Imaging.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|